New York, United States
TFC Therapeutics, founded in 2023, is a cutting-edge biotechnology company based in the United States. Specializing in biopharma, the firm's mission, as encapsulated in its slogan, is to develop novel biologics that tackle key cancer drivers, aiming to eradicate cancer recurrence and metastasis.
The company's strategy involves integrating early-stage research with a pioneering platform design to create next-gen treatments. This approach targets the most resilient cancers, striving to preemptively halt their recurrence.
TFC Therapeutics recently received a Pre Seed Round investment on 17 August 2023. This round attracted investments from notable backers, including Breakout Ventures, Arch Venture Partners, Alexandria Real Estate Equities, and Alumni Ventures. Their support underscores confidence in TFC's potential to innovate within the challenging oncology space.
